公开(公告)号：US20230277471A1

公开(公告)日：2023-09-07

申请号：US18126251

申请日：2023-03-24

申请人： THERASYN SENSORS, INC

发明人： Jerome J. Schentag ,  Mary P. McCourt ,  Lawrence Mielnicki ,  Julie Hughes

IPC分类号： A61K9/51 ,  A61K9/127 ,  A61K31/12 ,  A61K31/137 ,  A61K31/19 ,  A61K31/546 ,  A61K31/7034 ,  A61K31/713 ,  A61K38/14 ,  A61K38/28 ,  A61K39/29 ,  A61K39/395 ,  A61K45/06

CPC分类号： A61K9/51 ,  A61K9/127 ,  A61K9/1275 ,  A61K31/12 ,  A61K31/137 ,  A61K31/19 ,  A61K31/546 ,  A61K31/7034 ,  A61K31/713 ,  A61K38/14 ,  A61K38/28 ,  A61K39/29 ,  A61K39/3955 ,  A61K45/06

摘要： The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.

公开(公告)号：US20230270696A1

公开(公告)日：2023-08-31

申请号：US18314781

申请日：2023-05-09

申请人： Dan CHEN

发明人： JUN-PING LIU

IPC分类号： A61K31/137 ,  A61P25/28 ,  A61K9/00

CPC分类号： A61K31/137 ,  A61P25/28 ,  A61K9/0053

摘要： Provided is a medicinal use of fingolimod as sphingomyelinase inhibitor in preventing and treating neurodegenerative diseases caused by sphingolipid disorders. Research has shown that fingolimod can effectively alleviate and significantly improve the motion function of spastic paraplegic mice, enable old paraplegic mice to stand again, and increase the number of times paraplegic mice stand. Meanwhile, the present invention can effectively reduce/lower lipofuscin deposition and axonal myelin sheath tear in mouse brain tissue, can significantly alleviate the reduction or deficiency of sphingomyelin, promote the recycling of sphingomyelin, and correct neurological dysfunction caused by sphingolipid disorders that are due to a sphingomyelin deficiency. Further provided is an application of fingolimod in the preparation of a drug for preventing and treating neurodegenerative diseases caused by sphingolipid disorders.

公开(公告)号：US11738028B2

公开(公告)日：2023-08-29

申请号：US17388277

申请日：2021-07-29

申请人： Novartis AG

发明人： Jay Prakash Jain ,  Franz Joel Leong ,  Cornelis Winnips ,  Marie-Christine Wolf

IPC分类号： A61K31/522 ,  A61K31/137 ,  A61P33/06 ,  A61K31/4985 ,  A61K45/06

CPC分类号： A61K31/522 ,  A61K31/137 ,  A61K31/4985 ,  A61K45/06 ,  A61P33/06 ,  A61K2300/00 ,  A61K31/4985 ,  A61K2300/00 ,  A61K31/137 ,  A61K2300/00

摘要： The present invention relates to dosing regimen of a new antimalarial drug, as monotherapy or combination therapy.

公开(公告)号：US20230263466A1

公开(公告)日：2023-08-24

申请号：US18163244

申请日：2023-02-01

申请人： Massachusetts Institute of Technology

发明人： Taylor Baum ,  Emery Brown

IPC分类号： A61B5/00 ,  A61B5/021 ,  A61B5/02 ,  A61M5/172 ,  A61M5/168 ,  A61K31/137 ,  A61K31/4422

CPC分类号： A61B5/4839 ,  A61B5/021 ,  A61B5/02007 ,  A61M5/1723 ,  A61M5/16877 ,  A61K31/137 ,  A61K31/4422

摘要： A closed-loop system for blood pressure control that accounts for various mechanisms of the cardiovascular system. In some example cases, a pharmacokinetic-pharmacodynamic model of the cardiovascular system's response to cardiovascular system actuators, such as vasoactive drugs, is generated. Two example actuators are employed in the example framework: phenylephrine, to raise blood pressure, and nicardipine, to lower blood pressure. The pharmacodynamic components employs a two-element Windkessel model. A model predictive control framework is built based on the pharmacokinetic-pharmacodynamic model.

公开(公告)号：US11730706B1

公开(公告)日：2023-08-22

申请号：US18158268

申请日：2023-01-23

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/137 ,  A61P25/24 ,  A61K9/20 ,  A61K31/485

CPC分类号： A61K31/137 ,  A61K9/2086 ,  A61K31/485 ,  A61P25/24

摘要： This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prologation.

公开(公告)号：US20230257349A1

公开(公告)日：2023-08-17

申请号：US17885683

申请日：2022-08-11

申请人： Arena Pharmaceuticals, Inc.

发明人： Robert M. Jones ,  Daniel J. Buzard ,  Sangdon Han ,  Sun Hee Kim ,  Juerg Lehmann ,  Brett Ullman ,  Jeanne V. Moody ,  Xiuwen Zhu ,  Scott Stirn

IPC分类号： C07D209/94 ,  A61K31/404 ,  A61K31/497 ,  A61K31/4439 ,  A61K31/433 ,  A61K31/198 ,  A61K31/137 ,  C07D209/70 ,  C07D209/88 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07C211/27 ,  C07C229/26 ,  C07C255/03 ,  C07C279/14 ,  C07D401/14

CPC分类号： C07D209/94 ,  A61K31/404 ,  A61K31/497 ,  A61K31/4439 ,  A61K31/433 ,  A61K31/198 ,  A61K31/137 ,  C07D209/70 ,  C07D209/88 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07C211/27 ,  C07C229/26 ,  C07C255/03 ,  C07C279/14 ,  C07D401/14 ,  Y02A50/30

摘要： The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor.




Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.

公开(公告)号：US11723974B2

公开(公告)日：2023-08-15

申请号：US17115618

申请日：2020-12-08

申请人： Sanofi Biotechnology

发明人： Paul Bryce ,  Emanuele De Rinaldis ,  Ramon Antonio Hernandez Vecino ,  Francisco Javier Jimenez Jimenez ,  Cliona Marie Molony

IPC分类号： A61K39/395 ,  A61K9/00 ,  A61K45/06 ,  C07K16/28 ,  G06N20/00 ,  A61K31/137 ,  A61K31/522 ,  A61K31/56 ,  A61K31/573 ,  A61K39/00

CPC分类号： A61K39/3955 ,  A61K9/0019 ,  A61K31/137 ,  A61K31/522 ,  A61K31/56 ,  A61K31/573 ,  A61K45/06 ,  C07K16/2866 ,  G06N20/00 ,  A61K2039/545 ,  C07K2317/565

摘要： Disclosed are methods of treating various disorders with anti-IL-4Rα antibodies and fragments thereof.

公开(公告)号：US11723895B2

公开(公告)日：2023-08-15

申请号：US17197100

申请日：2021-03-10

申请人： Enzo Biochem, Inc.

发明人： Elazar Rabbani

IPC分类号： A61K31/137 ,  A61K31/4245

CPC分类号： A61K31/4245 ,  A61K31/137

摘要： The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.

公开(公告)号：US20230251273A1

公开(公告)日：2023-08-10

申请号：US17812058

申请日：2022-07-12

申请人： University of Miami

发明人： Juan Pablo DE RIVERO VACCARI ,  Robert W. KEANE ,  W. Dalton DIETRICH ,  Helen BRAMLETT

IPC分类号： G01N33/68 ,  A61K31/136 ,  A61K31/137 ,  A61K31/225 ,  A61K31/277 ,  A61K38/02 ,  A61K38/21 ,  A61K39/395

CPC分类号： G01N33/6893 ,  A61K31/136 ,  A61K31/137 ,  A61K31/225 ,  A61K31/277 ,  A61K38/02 ,  A61K38/215 ,  A61K39/3955 ,  G01N33/6896 ,  G01N2333/54 ,  G01N2333/545 ,  G01N2333/96469 ,  G01N2800/285 ,  G01N2800/2871

摘要： The present invention provides compositions and methods for detecting components of the inflammasome in a sample from a subject as markers for brain injuries such as multiple sclerosis, stroke or traumatic brain injury. Methods of using such inflammasome markers to determine prognosis, direct treatment and monitor response to treatment for the subject with a brain injury such as multiple sclerosis, stroke, mild cognitive impairment or traumatic brain injury are also described.

公开(公告)号：US20230248668A1

公开(公告)日：2023-08-10

申请号：US18300318

申请日：2023-04-13

申请人： AXSOME THERAPEUTICS, INC.

发明人： Herriot Tabuteau

IPC分类号： A61K31/137 ,  A61P25/28

CPC分类号： A61K31/137 ,  A61P25/28

摘要： This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as an enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.